ArticleChest2019
Rituximab Monotherapy for Common Variable Immune Deficiency-Associated Granulomatous-Lymphocytic Interstitial Lung Disease.
Article in Chest, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic testing for interstitial lung disease in common variable immunodeficiency: a systematic review.Frontiers in immunology · 2023Pooled it
- Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review.Frontiers in immunology · 2021Pooled it
- What Works When Treating Granulomatous Disease in Genetically Undefined CVID? A Systematic Review.Frontiers in immunology · 2020Pooled it
- Could belimumab be a new weapon in autoimmune complicated CVID?Frontiers in immunology · 2026Article
- Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease: From Immunopathogenesis to Therapeutic Implications.International journal of molecular sciences · 2025Review
- CXCL13 as a Biomarker of Complex Common Variable Immunodeficiency.Journal of clinical immunology · 2025Article
- Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas.Journal for immunotherapy of cancer · 2025Article
- Lymphocytic Interstitial Pneumonia Presenting as an Enlarging Pulmonary Nodule in a 65-Year-Old Woman: A Case Report.Cureus · 2025Article
- Rare interstitial lung diseases: a narrative review.Journal of thoracic disease · 2024Review
- Approach to diagnosing and managing granulomatous-lymphocytic interstitial lung disease.EClinicalMedicine · 2024Review
- Sarcoidosis versus Granulomatous and Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency: A Comparative Review.Biomedicines · 2024Review
- Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients.Journal of clinical immunology · 2023Article
- Lymphoid stromal cells - potential implications for the pathogenesis of CVID.Frontiers in immunology · 2023Review
- Non-infectious Pulmonary Complications in Children with Primary Immunodeficiency.Clinical medicine insights. Pediatrics · 2023Review
- Suboptimal Humoral Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Viral Variant Generation.Clinics in laboratory medicine · 2022Review
- Granulomatous-Lymphocytic Interstitial Lung Disease Mimicking Sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2021Article
- Interstitial Lung Disease in Common Variable Immunodeficiency.Frontiers in immunology · 2021Article
- From infections to autoimmunity: Diagnostic challenges in common variable immunodeficiency.World journal of clinical cases · 2020Review
- A double-edged sword.Breathe (Sheffield, England) · 2020Article
- Granulomatous lymphocytic interstitial lung disease: limiting immunosuppressive therapy-a single-centre experience.Respirology case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Patients with common variable immunodeficiency (CVID) can develop granulomatous-lymphocytic interstitial lung disease (GLILD), which is associated with increased morbidity and mortality. Treating GLILD is a significant challenge because it is rare and can be pathologically heterogeneous. Here we describe two cases of patients with CVID-associated GLILD with biopsies demonstrating loosely organized tertiary lymphoid structures (TLSs). Based on the pivotal role that B cells play in TLS initiation and maintenance, we hypothesized that using rituximab monotherapy for B-cell depletion alone would be sufficient for the disruption of the pathologic process underlying GLILD. These two cases demonstrate that adapting a strategy of B cell depletion monotherapy may be effective in TLS-associated conditions such as GLILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.